Home Stock

Stock Research: Glenmark Pharmaceuticals

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Glenmark Pharmaceuticals

NSEI:GLENMARK INE935A01035
53
  • Value
    46
  • Growth
    85
  • Safety
    Safety
    16
  • Combined
    40
  • Sentiment
    69
  • 360° View
    360° View
    53
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. It operates in branded, generics, and OTC segments, focusing on Respiratory, Dermatology, Oncology, diabetes, cardiovascular, and oral contraceptives, with brands like RYALTRIS and SALMEX/ASTHMEX. The company develops products for markets such as India, Russia & CIS, Brazil, Asia, and Africa. In the last fiscal year, the company had a market cap of $7238 million, profits of $1050 million, and revenue of $1559 million.

more
Strongest Rank Opinions Change
Weakest Rank Pro Holdings
Country India
Industry Pharmaceuticals
Size Small
Website glenmarkpharma.com
Index
Low Waste
Recycling
Glenmark Pharmaceuticals stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 18-Dec-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
46 59 71 87
Growth
85 77 23 37
Safety
Safety
16 18 44 29
Sentiment
69 61 32 14
360° View
360° View
53 66 28 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
84 60 31 42
Opinions Change
12 50 38 35
Pro Holdings
n/a 25 21 26
Market Pulse
47 96 73 47
Sentiment
69 61 32 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
46 59 71 87
Growth
85 77 23 37
Safety Safety
16 18 44 29
Combined
40 54 39 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
56 64 75 89
Price vs. Earnings (P/E)
62 62 84 91
Price vs. Book (P/B)
41 59 81 87
Dividend Yield
23 18 23 40
Value
46 59 71 87
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
21 67 28 16
Profit Growth
92 98 26 53
Capital Growth
45 3 6 72
Stock Returns
93 95 95 33
Growth
85 77 23 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
28 46 26 18
Refinancing
41 28 76 84
Liquidity
25 14 38 24
Safety Safety
16 18 44 29

Similar Stocks

Discover high‑ranked alternatives to Glenmark Pharmaceuticals and broaden your portfolio horizons.

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Fleury

BOVESPA:FLRY3
Country: Brazil
Industry: Health Care Services
Size: Medium
Full Stock Analysis

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Bosch

BSE:500530
Country: India
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a classic, high-risk growth play: high growth and positive sentiment outweigh low Value Rank (expensive) and risky financing. This is for aggressive growth investors who are comfortable with the high price and risk, believing the growth story justifies the expense.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews